21:24 , May 11, 2017 |  BC Innovations  |  Translation in Brief

Going universal

Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) is going allogeneic and ditching antigen specificity to broaden the reach of its chimeric antigen receptor (CAR)-expressing T cells. By suppressing endogenous T cell receptor (TCR) expression and using NK cell...